Breaking Science News Today

GNW-Adhoc: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 () | aktiencheck.de

The International Stroke Conference 2024 will be held Feb. 7-9 in Phoenix, Arizona. According to program planners with the American Stroke Association, a division of the American Heart Association, findings from late-breaking science will include multiple high profile randomized clinical trials like RESILIENT-Extend, EMBOLISE, STEM, ZODIAC, among many others.

With nine Hot Line sessions, four new guidelines, 3,500 abstracts, and more, time will be tight for visiting your favorite Vermeer.

GNW-Adhoc: New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 202 () | aktiencheck.de

^Allschwil, Switzerland - June 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia's investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, will be presented as an oral presentation by Prof. M...

^Allschwil, Switzerland - June 23, 2023

Heart Rhythm 2023, the society's 44th annual meeting, takes place May 19-21, in New Orleans

In a real-world population, pulsed field ablation using a novel catheter was safe for most patients with atrial fibrillation in routine practice, with 78% free from AF at 1 year, registry data show. Pulsed field ablation (PFA) is a novel AF ablation modality that has demonstrated preferential tissue ablation with no esophageal damage in early clinical trials, Vivek Y. Reddy, MD, director of

In a small, single-center trial, the novel Marshall-Plan ablation strategy improved 10-month arrhythmia recurrence compared with pulmonary vein isolation alone for persistent atrial fibrillation, a speaker reported.“After 10 months of follow up, the success rate in the Marshall-Plan group was significantly better (87%) compared to the PVI only group (70%),” Nicolas Derval, MD, head of

The novel ANTWERP score demonstrated good predictive value in identifying patients whose heart failure symptoms would improve after ablation for atrial fibrillation, a speaker reported.The score utilized readily available clinical values including QRS width, known etiology, AF subtype and atrial dilation to identify those who may experience improved left ventricular ejection fraction after AF